Andersen et al. [25] reported the detection of HLA-A24 restricted and survivin peptide-specific CD8-positive cells by IFN-γ ELISPOT assay and perforin ELISPOT assay in patients with breast cancer, melanoma and renal cancer. This evidence concerns the gene CD8A and melanoma.